VSI has been conducting endovascular workshops for the vascular trainees and has arranged for fellowships abroad in reputed vascular units. VSI is looking forward to having active interaction with World Federation of Vascular Societies to create more training opportunities for the young vascular surgeons. (J Vasc Surg 2008;4.8:76S-80S.)”
“Treatment of TRAIL-resistant tumor cells

with the nitric oxide donor DETANONOate sensitizes the tumor cells to TRAIL-induced apoptosis concomitantly with DR5 upregulation. The mechanism of sensitization was examined based on the hypothesis that DETANONOate inhibits a transcription FK506 repressor Yin Yang 1 (YY1) that negatively regulates DR5 transcription. Treatment of the prostate carcinoma cell lines with DETANONOate inhibited both NF-kappa B and YY1 DNA-binding Torin 2 solubility dmso activities concomitantly with upregulation of DR5

expression. The direct role of YY1 in the regulation of TRAIL resistance was demonstrated in cells treated with YY1 siRNA resulting in TRAIL-induced apoptosis. The role of YY1 in the transcriptional regulation of DR5 was examined in cells treated with a DR5 luciferase reporter system (pDR5) and two constructs, namely, the pDR5/-605 construct with a deletion of the putative YY1 DNA-binding region (-1224 to -605) and a construct pDR5-YY1 with a mutation of the YY1 DNA-binding site. A significant (3-fold) augmentation of luciferase activity over baseline transfection with

pDR5 was observed in cells transfected with the modified constructs. ChIP analysis corroborated the YY1 binding to the DRS promoter. In vivo, tissues from nude mice bearing the PC-3 xenograft and treated with DETANONOate showed inhibition of YY1 and upregulation of DRS. The present findings demonstrate that YY1 negatively regulates DR5 transcription and expression and these correlated with resistance to TRAIL-induced apoptosis. DETANONOate inhibits both NF-kappa B and YY1 and in combination with TRAIL reverses tumor cell resistance to Adenosine triphosphate TRAIL apoptosis. (c) 2008 Elsevier Inc. All rights reserved.”
“Cardiovascular diseases have become more prevalent and threatening to the health of the population of Asia due to the rapidly growing number of aging people. The Asian Society for Vascular Surgery unites 13 member organizations: Japan, Korea, China, India, Hong Kong, Singapore, Malaysia, Taiwan, Bangladesh, Philippines, Saudi Arabia, Indonesia, and Thailand. The essential mission of the Asian Society for Vascular Surgery is to improve training in vascular surgery to increase the number of competent vascular surgeons in Asia. Almost every member country has its own vascular training program.